MaxCyte SPL Portfolio

November 12, 2025

MaxCyte® expert® ATx® STx® GTx® VLx® are registered trademarks of MaxCyte, Inc. in the U.S.A.

MaxCyte has an Active Portfolio of SPLs

Durable revenue is supported by 14 SPL clients with 18 active clinical programs, and 1 commercial program

- cGMP Compatible Platform
- FDA Master File and Technical Files
- Experienced FAS and sales support
- Leading know-how and engineering process improvement

SPL with active clinical trial

18 Active Clinical Programs Represents ~$210M of precommercial milestone potential[1]

32 SPL Agreements → **14** SPLs with Active Clinical Trials → **18** Programs are currently in clinical development* → **1** Commercial Program*

Cleared INDs or Equivalent

**Updated as of August 6, 2025*

CARIBOU BIOSCIENCES, LION TCR, editas MEDICINE, Kite A GILEAD Company, KSQ, invios INNOVATIVE IMMUNO-ONCOLOGY, Beam Therapeutics, VERTEX, celularity, prime medicine, nkarta THERAPEUTICS, CRISPR THERAPEUTICS, WALKING FISH THERAPEUTICS, Lyell Immunopharma, VOR BIOPHARMA, Sana Biotechnology, INTIMA BIOSCIENCE, Allogene THERAPEUTICS, curamys, VITTORIA biotherapeutics, IMUGENE, MYELOID Therapeutics, Inc., LG Chem, catamaranBIO, Adicet Bio, Wugen, BIOPHARMA, LEGEND BIOTECH, KAMAU THERAPEUTICS, TG Therapeutics, anocca, MOON LIGHT BIO

1. Inclusive of ~$10 million of milestones already received by MaxCyte

SPL Partners by Financing Stage

Private: Seed/Series A

Private: Series B/C

Public Company



Notable 2025 Financing:

- Adicet Bio: $80M Public Financing October 2025
- Anocca AB: $46M Private Financing August 2025
- Wugen: $115M Series C Private Financing August 2025
- Beam Therapeutics: $500M Public Financing March 2025
- Be Biopharma: Closed $92M Series C Private Financing January 2025

Wound down

SPL with active clinical trial

SPL Portfolio: 22 Active Clinical Trials

Clinical Phase

- Phase 1
- Phase 1/2
- Pivotal
- Commercial

Cell Approach

- Allogeneic
- Autologous



As of August 2025 / Includes with SPL Programs with multiple Clinical Trials for different indications

Indications in Active MaxCyte-Enabled Clinical Trials

Genetic Diseases
Beta-Thalassemia
Sickle Cell Disease
Hemophilia B
Chronic Granulomatous Disease (CGD)

Solid Tumors
Non-small Cell Lung Cancer
Head and Neck Cancer
Glioblastoma
Renal Cell Carcinoma
Melanoma
Other Solid Tumors

Hematological Malignancies
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Multiple Myeloma
Non-Hodgkin Lymphoma
T Cell Lymphoma

Autoimmune Disease
Lupus Nephritis
ANCA-associated Vasculitis
Multiple Sclerosis
Type 1 Diabetes
Other autoimmune diseases

Expanding Opportunity: Growth in Therapeutic Areas and Clinical SPL Programs

SPL Trials Across Multiple Therapeutic Areas

Therapeutic Area	Clinical/ Commercial	Pre-Clinical
Genetic Disease	4	3
Blood Cancer	8	1
Solid Tumor	5	14
Autoimmune Disease	5	1
Neurodegenerative Disease	0	1
Total	**22**	**20**

SPL Programs (Clinical & Commercial) and Licensed Partners (SPL) Nearly Double in Last 5 Years



MaxCyte Supports the Future of Cell & Gene Therapies

WAVE 1	WAVE 2	WAVE 3	WAVE 4
1 Approved Product	5 Product Candidates	13 Product Candidates	20 Product Candidates
Vertex/ CRISPR CASGEVY® **Approved 2023** **US FDA, European Commission & Additional Regulatory Bodies**	**Launch Potential: 2027 – 2028** **5 products set to enter pivotal studies in next 6 to 18 months**	**Launch Potential: 2028 +** **13 products currently in Phase 1**	**Launch Potential: 2032 +** **20 products in preclinical development**

MaxCyte's supports a diverse portfolio of product candidates with significant development milestone and commercial royalty potential

Source: Evaluate Pharma, Broker Estimates and MaxCyte Internal Estimates as of August 2025

Second Wave Set to Enter Pivotal Studies in Next 6 to 18 Months

SPL	Clinical Programs	Phase	Cell Type	Cell Approach	Indication
CRISPR THERAPEUTICS	CTX112	1/2	T-cells	Allogeneic	B-cell Malignancies
Wugen	WU-CART-007	2	T-cells	Allogeneic	Hematologic Malignancies
IMUGENE	Azer-Cel	1/1b	T-Cells	Allogeneic	Hematologic Malignancies
CARIBOU BIOSCIENCES	CB010	1	T-Cells	Allogeneic	Hematologic Malignancies
Undisclosed	*Undisclosed Program*	1/2	*Undisclosed*	*Undisclosed*	*Undisclosed*

Illustrative Revenue Profile for a Successful SPL Program

Revenue Growth Drivers: Significant development milestones and high-value participation in future commercial success of partners' programs

Assumptions: First Approval in Year 7 | Approval in Three Geographic Regions
$1.0B Peak Sales | Peak Sales Commercial Year 7 | Royalty 1.0%



Thank you!
Any questions?

ir@maxcyte.com